Supyra®

S Kant Healthcare

Legend
Product category

  • Seasonal malaria chemoprevention (sulfadoxine-pyrimethamine + amodiaquine)
Therapeutic indication

  • Seasonal malaria chemoprevention (SMC) for children 3 to 59 months in eligible region
Dosing

  • Once daily for 3 days (amodiaquine) and one day (sulfadoxine-pyrimethamine), administered in monthly cycles for 4 months
Efficacy

  • 75% reduction in malaria episodes in pivotal trials
Key features

  • Recommended by WHO for the prevention of malaria in children in areas of high seasonal malaria transmission

  • Two-year shelf life
Challenges
  • Drug distribution to healthy subjects mainly via door-to-door campaigns
Status
  • The Global Fund ERP approved for one year until Feb 2020
  • Registered in 4 countries; ongoing in 5 other countries
  • Orders confirmed for >11 million treatments in 2019
Next milestone

  • WHO prequalification

  • Extension of the recommendation for children up to their 10th birthday
  •  Validation of the dose and development of a specific packaging for children from 5 years old up until their 10th birthday
  •  Exploration of expanded SMC coverage by adding a fifth monthly round of treatment in areas with longer seasonal transmission
MMV Project Director

  • Dr André-Marie Tchouatieu